Lu-177 DOTATATE therapy, also called peptide receptor radionuclide therapy (PRRT), is a targeted treatment for advanced neuroendocrine tumours. It uses DOTATATE to carry radioactive lutetium-177 to somatostatin receptors on tumour cells, delivering radiation while limiting exposure to nearby healthy tissue. It is recommended for patients whose tumours show receptor uptake on specialised scans. Kidney function and blood counts are checked before treatment to ensure it is suitable.
According to Dr. Gayana Shankaramurthy, a Nuclear Medicine Specialist in Bangalore at KIMS Hospitals, the infusion is the quick part, and what counts is the scan before it. “The medicine can only act on a tumour that carries the right receptors, and the scan shows whether it does. Blood counts and kidney function then decide whether treatment can go ahead safely,” she explains.
Who Needs Lu-177 DOTATATE Therapy, and When Do Doctors Consider It?
The usual patient has a neuroendocrine tumour (NET) that has spread, or one that surgery can’t fully remove. Small bowel and pancreatic NETs are the common ones, and lung NETs turn up less often. There’s one more condition. The tumour has to show enough somatostatin receptors for the medicine to hold on to, and only a special scan can tell. The question tends to arise when scans show the disease growing even with somatostatin analogue injections, which are the usual first medicine for many NETs.
NETTER-1 is the trial most often quoted. Of the 229 patients, all with advanced midgut NETs that had kept growing on octreotide, about half were given Lu-177 DOTATATE and the rest a higher dose of octreotide. At 20 months, progression-free survival was estimated at 65.2% in the first group and 10.8% in the second. That’s one trial, in one tumour type, so it can’t be stretched to everyone. Each case is judged by itself. More on how scans and treatment are paired for these tumours is on the Theranostics in NET page.
Not everyone is a candidate. A tumour that shows little tracer on the scan gives the medicine nothing to bind to. Kidney or bone marrow function that’s seriously reduced calls for extra care, pregnancy is a reason to avoid treatment, and breastfeeding has to stop if it goes ahead.
Wondering if Lu-177 DOTATATE therapy is right for your neuroendocrine tumor? Book a consultation to find out who it suits.
How Is Lu-177 DOTATATE Therapy Given, and What Side Effects Can Follow?
The drip goes into a vein, usually in the arm. An amino acid solution runs alongside it, which protects the kidneys from the radiation they’d otherwise pick up. There’s no pain, but a few hours are blocked out for the visit. NETTER-1 gave four infusions roughly eight weeks apart, though schedules do vary from person to person.
|
Stage |
What happens |
What the patient may notice |
|
Before treatment |
A somatostatin receptor scan, plus blood and kidney tests |
Usually nothing beyond the scan itself |
|
Infusion day |
Lu-177 DOTATATE is infused together with the amino acid solution |
Nausea or vomiting in some people |
|
Afterwards |
Radiation precautions at home for a few days, then blood tests and follow-up scans |
Tiredness for a few days |
Before treatment starts, a somatostatin receptor PET/CT checks whether the tumour takes up the tracer, and the PET/CT page explains how these scans work.
What Determines the Lu-177 DOTATATE Treatment Plan and the Number of Cycles?
Lu-177 DOTATATE therapy is a targeted radionuclide treatment for neuroendocrine tumours that carry somatostatin receptors, and it is given in cycles. The treating team begins with the scan. How brightly the tumour lights up on that scan is the first test of whether the receptors are there in useful numbers. The remaining pieces are tumour grade, how far the disease has spread, earlier treatments, kidney function, blood counts and the patient’s general fitness. Together, these points decide how many cycles are given and how far apart. Blood tests are repeated before every cycle to confirm it’s safe to proceed. After the course, follow-up scans show how the tumour has behaved, and the next step is planned from there.
Key Takeaways
- Lu-177 DOTATATE therapy is a type of PRRT. It delivers radiation directly to tumour cells that carry somatostatin receptors.
- It’s considered mainly for advanced tumours with enough receptors, often after other medicines have stopped working well.
- It’s infused into a vein with an amino acid solution, normally over several cycles.
- Nausea, tiredness and lower blood counts for a while are the main side effects, and blood tests track the counts.
- No two plans are quite alike. Scan results, kidney function, blood counts and general health all feed into each one.
Frequently Asked Questions
What is Lu-177 DOTATATE therapy and how does it work?
Lu-177 DOTATATE is a targeted radionuclide therapy that binds to receptors on tumour cells and delivers radiation directly to them.
Who needs Lu-177 DOTATATE therapy?
Patients whose advanced neuroendocrine tumour shows somatostatin receptors on PET/CT.
Does Lu-177 DOTATATE therapy hurt?
Usually no. It’s given through a vein, though nausea can occur.
How many sessions of Lu-177 DOTATATE therapy are needed?
Commonly four, about eight weeks apart. The treating doctor decides the exact number.
References:
- PMC, Strosberg J et al., Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1), N Engl J Med 2017: https://pmc.ncbi.nlm.nih.gov/articles/PMC5895095/
- PubMed, Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update, Curr Oncol Rep 2024: https://pubmed.ncbi.nlm.nih.gov/38581469/
Disclaimer:This blog is for educational purposes only and isn’t a substitute for professional medical advice.